[go: up one dir, main page]

WO2006062477A1 - Chemical process - Google Patents

Chemical process Download PDF

Info

Publication number
WO2006062477A1
WO2006062477A1 PCT/SE2005/001865 SE2005001865W WO2006062477A1 WO 2006062477 A1 WO2006062477 A1 WO 2006062477A1 SE 2005001865 W SE2005001865 W SE 2005001865W WO 2006062477 A1 WO2006062477 A1 WO 2006062477A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
acetic acid
zinc
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2005/001865
Other languages
French (fr)
Inventor
Matthew Perry
Brian Springthorpe
Linda Stein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of WO2006062477A1 publication Critical patent/WO2006062477A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
    • C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
    • C07C29/14—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of a —CHO group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/23—Preparation of halogenated hydrocarbons by dehalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/02—Monocyclic aromatic halogenated hydrocarbons
    • C07C25/13—Monocyclic aromatic halogenated hydrocarbons containing fluorine

Definitions

  • the present invention concerns a process for the preparation of 3-methyl-l,2- dichloro-4-fluorobenzene.
  • 3-Methyl-l,2-dichloro-4-fluorobenzene is useful in the preparation of modulators (for example antagonists) of CCR3 chemokine receptor activity.
  • modulators for example antagonists
  • 3-methyl- l,2-dichloro-4-fluorobenzene is a useful pharmaceutical intermediate in the preparation of [(phenoxy)-[l,4']bipiperidinyl-r-yl] derivatives (see, for example, WO 03/004487, WO2004/099144 and WO2004/087659).
  • the present invention provides a process for the preparation of a compound of formula (I):
  • the present invention provides a process for preparing a compound of formula (I), the process comprising: a. reacting a compound of formula (II):
  • X is halogen (such as bromo or iodo); and, e. reducing compound or formula (V) with zinc and acetic acid to produce a compound of formula (I).
  • Suitable strong bases are, for example, C 1-1 O alkyl (for example Ci -6 alkyl, such as C 4 ) lithiums (such as «-butyl lithium or .sec-butyl lithium), a di-Ci -10 alkyl (for example di- C 1-6 alkyl) lithium amide base (such as lithium diwo-propylamide), an aryl lithium (such as a phenyl lithium) or an arylalkyl lithium (such as a benzyl lithium).
  • C 1-1 O alkyl for example Ci -6 alkyl, such as C 4
  • lithiums such as «-butyl lithium or .sec-butyl lithium
  • a di-Ci -10 alkyl for example di- C 1-6 alkyl
  • lithium amide base such as lithium diwo-propylamide
  • an aryl lithium such as a phenyl lithium
  • an arylalkyl lithium such as a benzyl lithium
  • a suitable strong base is, for example a C 1-6 alkyl (such as a C 1-4 alkyl, for example a C 4 ) lithium (such as «-butyl lithium or sec-butyl lithium) or a di-Ci -6 alkyl lithium amide base (such as lithium diwo-propylamide).
  • the strong base is «-butyl lithium.
  • a suitable solvent for formation of an aldehyde of formula (III) from a compound of formula (II) is an ether (for example tetrahydrofuran [THF], methyl fert-butyl ether or dioxan).
  • Suitable halogenating agents for the preparation of a compound of formula (V) include: trimethylsilyl iodide; triphenylphosphine and iodine (for example using acetonitrile as solvent); thionyl bromide; and, hydrogen bromide in acetic acid.
  • the reduction with zinc and acetic acid is suitably carried out by slowly (typically over 0.5 h) adding the compound of formula (V) to the mixture of zinc and acetic acid.
  • the halogenation of a compound of formula (IV) uses hydrogen bromide in acetic acid then the reduction with zinc and acetic acid can be conducted by adding the reaction mixture resulting from the halogenation reaction directly to zinc in acetic acid.
  • the reduction with zinc and acetic acid is conducted at low concentration (for example by having a slow addition of the compound (V)) to minimise Wurtz-type coupling.
  • the compound of formula (V) is extracted from reaction mixture of the reduction with zinc and acetic acid by extraction of the reaction mixture with pentane and then evaporation of the pentane to leave the title compound.
  • the present invention provides a process as hereinbefore described wherein between 1 and 1.5 molar equivalents of strong base is used ⁇ for example between 1.3 equivalents of strong base ⁇ .
  • the present invention provides a process as hereinbefore described wherein between 0.3 and 0.6 molar equivalents (for example 0.35 to 0.45 molar equivalents) alkali metal borohydride are used.
  • Triphenylphosphine (3.22 g), imidazole (0.84 g) and iodine (3.12 g) were added, in that order, to acetonitrile (20 mL).
  • a solution of (2,3-dichloro-6-fluorophenyl)methanol (2 g) in acetonitrile (10 mL) was added and the mixture was stirred at room temperature, under nitrogen, for 0.5 h.
  • LC/MS showed that all of the starting alcohol had been consumed and a new peak, believed to be the benzyl iodide had appeared; retention time 2.71 minutes on standard gradient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention concerns a process for the preparation of a compound of formula (I): the process comprising a. reducing aldehyde of formula (III): with an alkali metal borohydride in ethanol to give compound of formula (IV): b. halogenating a compound of formula (IV) with a halogenating agent to form a compound of formula (V): wherein X is halogen; and, c. reducing compound or formula (V) with zinc and acetic acid to produce a compound of formula (I).

Description

CHEMICAL PROCESS
The present invention concerns a process for the preparation of 3-methyl-l,2- dichloro-4-fluorobenzene.
3-Methyl-l,2-dichloro-4-fluorobenzene is useful in the preparation of modulators (for example antagonists) of CCR3 chemokine receptor activity. For example 3-methyl- l,2-dichloro-4-fluorobenzene is a useful pharmaceutical intermediate in the preparation of [(phenoxy)-[l,4']bipiperidinyl-r-yl] derivatives (see, for example, WO 03/004487, WO2004/099144 and WO2004/087659).
Thus, the present invention provides a process for the preparation of a compound of formula (I):
Figure imgf000002_0001
herein referred to as l,2-dichloro-4-fluoro-3-methylbenzene, the process comprising: a. reducing aldehyde of formula (III):
CHO
Figure imgf000002_0002
with an alkali metal borohydride (such as sodium borohydride) in ethanol to give compound of formula (IV):
Figure imgf000002_0003
b. halogenating a compound of formula (JV) with a halogenating agent to form a compound of formula (V):
(V)
Figure imgf000002_0004
wherein X is halogen (such as bromo or iodo); and, c. reducing compound or formula (V) with zinc and acetic acid to produce a compound of formula (I).
In one aspect the present invention provides a process for preparing a compound of formula (I), the process comprising: a. reacting a compound of formula (II):
Figure imgf000003_0001
with suitable strong base at a temperature in the range -80 to -30 0C in a suitable solvent to form a carbanion of a compound of formula (II); b. reacting the carbanion of a compound of formula (II) with a suitable formylating agent (such as N-methylformanilide or N,N-dimethylformamide) in a suitable solvent, and at a temperature in the range -80 to -30 0C (for example -50 to -30 0C) to give aldehyde of formula (III):
CHO
Figure imgf000003_0002
c. reducing the aldehyde of formula (III) with an alkali metal borohydride (such as sodium borohydride) in ethanol to give compound of formula (IV):
Figure imgf000003_0003
d. halogenating a compound of formula (IV) with a halogenating agent to form a compound of formula (V):
Figure imgf000003_0004
wherein X is halogen (such as bromo or iodo); and, e. reducing compound or formula (V) with zinc and acetic acid to produce a compound of formula (I).
Suitable strong bases are, for example, C1-1O alkyl (for example Ci-6 alkyl, such as C4) lithiums (such as «-butyl lithium or .sec-butyl lithium), a di-Ci-10 alkyl (for example di- C1-6 alkyl) lithium amide base (such as lithium diwo-propylamide), an aryl lithium (such as a phenyl lithium) or an arylalkyl lithium (such as a benzyl lithium).
In a still further aspect of the invention a suitable strong base is, for example a C1-6 alkyl (such as a C1-4 alkyl, for example a C4) lithium (such as «-butyl lithium or sec-butyl lithium) or a di-Ci-6 alkyl lithium amide base (such as lithium diwo-propylamide). In another aspect of the invention the strong base is «-butyl lithium. A suitable solvent for formation of an aldehyde of formula (III) from a compound of formula (II) is an ether (for example tetrahydrofuran [THF], methyl fert-butyl ether or dioxan).
Suitable halogenating agents for the preparation of a compound of formula (V) include: trimethylsilyl iodide; triphenylphosphine and iodine (for example using acetonitrile as solvent); thionyl bromide; and, hydrogen bromide in acetic acid.
The reduction with zinc and acetic acid is suitably carried out by slowly (typically over 0.5 h) adding the compound of formula (V) to the mixture of zinc and acetic acid. When the halogenation of a compound of formula (IV) uses hydrogen bromide in acetic acid then the reduction with zinc and acetic acid can be conducted by adding the reaction mixture resulting from the halogenation reaction directly to zinc in acetic acid.
In another aspect of the invention the reduction with zinc and acetic acid is conducted at low concentration (for example by having a slow addition of the compound (V)) to minimise Wurtz-type coupling.
In a further aspect of the invention the compound of formula (V) is extracted from reaction mixture of the reduction with zinc and acetic acid by extraction of the reaction mixture with pentane and then evaporation of the pentane to leave the title compound. In a still further aspect the present invention provides a process as hereinbefore described wherein between 1 and 1.5 molar equivalents of strong base is used {for example between 1.3 equivalents of strong base}. In another aspect the present invention provides a process as hereinbefore described wherein between 0.3 and 0.6 molar equivalents (for example 0.35 to 0.45 molar equivalents) alkali metal borohydride are used.
The invention will now be illustrated by the following non-limiting Examples. In the Examples the following apply, unless stated otherwise:
(i) when given, 1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300MHz or 400MHz using perdeuterio DMSO-D6 (CD3SOCD3) or CDCl3 as the solvent unless otherwise stated;
(ii) Reverse phase analytical HPLC was run on a Hewlett Packard Series 1100 using Waters "Symmetry" C8 column 3.5μm; 4.6 x 50mm column. The gradient was either:
"Standard" (0.1% Ammonium acetate/ Acetonitrile 75% to 5% in 3 min; 2 mL/min); Or,
"Fast" (0.1% Ammonium acetate/Acetonitrile 45% to 5% in 2.5 min; 2 mL/min); and, (iii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion - (M+H)+.
EXAMPLE 1
This Example illustrates the preparation of l,2-dichloro-4-fluoro-3-methylbenzene. a) (2,3-Dichloro-6-fluorophenyl)methanol
A solution of 2,3-dichloro-6-fluoro-benzaldehyde (80 g) in ethanol (250 ml) was added dropwise to a stirred suspension of sodium borohydride (7.8 g) in ethanol (150 ml) at a rate that maintained the internal reaction temperature below 10 °C. After complete addition, approximately 20 minutes, the mixture was allowed to reach ambient temperature. The mixture was evaporated to -1/4 volume and brine (200 ml) plus acetic acid (5 ml) was added cautiously to the stirred mixture. The resulting solid was extracted into diethyl ether (3 x 300 ml). The organic solution was dried over magnesium sulfate, filtered and evaporated to leave a solid. This solid was stirred in isohexane : ethyl acetate mixture (100:1, 300 ml) for 16 hours. The resulting solid was filtered and dried to give the subtitle compound as an off white solid (60 g). Mpt 90-92 0C NMR δcDcis: 7.42 (dd, IH), 7.01 (t, IH), 4.88 (d, 2H), 2.04 (t, IH). b) 2-Dichloro-4-fluoro-3 -(iodomethyl)benzene
Triphenylphosphine (3.22 g), imidazole (0.84 g) and iodine (3.12 g) were added, in that order, to acetonitrile (20 mL). A solution of (2,3-dichloro-6-fluorophenyl)methanol (2 g) in acetonitrile (10 mL) was added and the mixture was stirred at room temperature, under nitrogen, for 0.5 h. LC/MS showed that all of the starting alcohol had been consumed and a new peak, believed to be the benzyl iodide had appeared; retention time 2.71 minutes on standard gradient.
c) 1 ,2-Dichloro-4-fluoro-3-methylbenzene In an adjacent flask powdered zinc (3.27 g) was added to acetonitrile (10 mL) and to the suspension was added glacial acetic acid (10 mL). This was heated, under nitrogen, to 80 0C. The l,2-dichloro-4-fluoro-3-(iodomethyl)benzene solution, described above, was added dropwise over 0.5 hours to the hot zinc / acetic acid mixture. LC/MS showed that all of the starting benzyl iodide had been consumed and the required product had formed; retention time 2.63 minutes on standard gradient. The reaction mixture was allowed to cool to room temperature and filtered. The filtrate was extracted twice with pentane. The pentane was concentrated on a rotary evaporator with the bath at 40 0C but no vacuum applied to give the title compound (1.6 g; contains ca 10% acetonitrile by NMR).
1H NMR δ(CDci3): 2.34 (3H, d), 6.92 (IH, t), 7.24 - 7.30 (IH, m).
EXAMPLE 2 This Example illustrates the preparation of l,2-dichloro-4-fluoro-3-methylbenzene.
a) 1 ,2-Dichloro-4-fluoro-3-(bromomethyl)benzene 2,3-Dichloro-6-fluorophenyl)methanol (14.2 g) was dissolved in a solution of hydrogen bromide in acetic acid (140 mL) and the mixture was heated at 80 0C for 10 minutes. LC/MS showed that all of the starting material had been consumed and a new peak, corresponding to the required benzyl bromide, was visible; retention time 2.58 minutes on standard gradient. The reaction mixture was allowed to cool to room temperature.
b) l,2-dichloro-4-fluoro-3-methylbenzene
Powdered zinc (23.8 g) was added to acetonitrile (50 mL) and glacial acetic acid (50 mL) and the suspension was heated, under nitrogen, to 80 0C. The reaction mixture containing l,2-dichloro-4-fluoro-3-(bromomethyl)benzene in acetic acid containing hydrogen bromide, described above, was added dropwise to the hot zinc / acetic acid mixture over approximately 1 hour. LC/MS showed that the desired product had formed; retention time 2.63 minutes on standard gradient. The reaction mixture was allowed to cool to room temperature then filtered to remove the zinc. The filtrate was extracted with pentane (six times) and the solvent was removed on a rotary evaporator with the water bath at 40 0C and no vacuum to give the title compound (10.4 g).
1H NMR δ(cDci3): 2.34 (3H, d), 6.92 (IH, t), 7.24 - 7.30 (IH, m).

Claims

1. A process for the preparation of a compound of formula (I):
Figure imgf000008_0001
the process comprising: a. reducing aldehyde of formula (III):
CHO
Figure imgf000008_0002
with an alkali metal borohydride in ethanol to give compound of formula (IV):
Figure imgf000008_0003
b. halogenating a compound of formula (IV) with a halogenating agent to form a compound of formula (V):
Figure imgf000008_0004
wherein X is halogen; and, c. reducing compound or formula (V) with zinc and acetic acid to produce a compound of formula (I).
2. A process as claimed in claim 1 wherein the alkali metal borohydride is sodium borohydride.
3. A process as claimed in claim 1 or 2 wherein X is bromo or iodo.
4. A process as claimed in claim 1, 2 or 3 wherein the halogenating agent is: trimethylsilyl iodide; triphenylphosphine and iodine; thionyl bromide; or, hydrogen bromide and acetic acid.
5. A process as claimed in claim 1, 2, 3 or 4 wherein the reduction with zinc and acetic acid is suitably carried out by adding the compound of formula (V) to the mixture of zinc and acetic acid.
6. A process as claimed in claim 1, 2, 3, 4 or 5 wherein the compound of formula (V) is extracted from a reaction mixture of the reduction of compound of formula (IV) with zinc and acetic acid by extraction of the reaction mixture with pentane.
PCT/SE2005/001865 2004-12-09 2005-12-07 Chemical process Ceased WO2006062477A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0403004A SE0403004D0 (en) 2004-12-09 2004-12-09 Chemical compound II
SE0403004-5 2004-12-09

Publications (1)

Publication Number Publication Date
WO2006062477A1 true WO2006062477A1 (en) 2006-06-15

Family

ID=33550626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/001865 Ceased WO2006062477A1 (en) 2004-12-09 2005-12-07 Chemical process

Country Status (2)

Country Link
SE (1) SE0403004D0 (en)
WO (1) WO2006062477A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311786A (en) * 2016-05-02 2019-02-05 陶氏环球技术有限责任公司 Methods of Aromatic Fluorination
CN111196750A (en) * 2018-11-20 2020-05-26 清华大学 A kind of preparation method of benzyl iodide and derivatives thereof
CN112142544A (en) * 2019-06-27 2020-12-29 中国科学院上海有机化学研究所 A kind of method of halide hydrogenolysis
CN112898273A (en) * 2021-03-30 2021-06-04 海南锦瑞制药有限公司 Synthetic method and application of voriconazole

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEROUX F. ET AL: "N-(4-Biphenylmethyl)imidazoles as Potential Therapeutics for the Treatment of Prostate Cancer: Metabolic Robustness Due to Fluorine Substitution?", HELVETICA CHIMICA ACTA, vol. 86, 2003, pages 2671 - 2686, XP002996593 *
PASHA M.A. ET AL: "Zinc metal assisted hydro-de-halogenation of DDT into DDEthane under sonic conditions", INDIAN JOURNAL OF CHEMISTRY, vol. 41B, August 2002 (2002-08-01), pages 1747 - 1748, XP002996594 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311786A (en) * 2016-05-02 2019-02-05 陶氏环球技术有限责任公司 Methods of Aromatic Fluorination
CN109311786B (en) * 2016-05-02 2021-12-03 陶氏环球技术有限责任公司 Process for aromatic fluorination
CN111196750A (en) * 2018-11-20 2020-05-26 清华大学 A kind of preparation method of benzyl iodide and derivatives thereof
CN111196750B (en) * 2018-11-20 2020-11-10 清华大学 Preparation method of benzyl iodide and derivatives thereof
CN112142544A (en) * 2019-06-27 2020-12-29 中国科学院上海有机化学研究所 A kind of method of halide hydrogenolysis
CN112142544B (en) * 2019-06-27 2023-10-27 中国科学院上海有机化学研究所 A method for hydrogenolysis of halide
CN112898273A (en) * 2021-03-30 2021-06-04 海南锦瑞制药有限公司 Synthetic method and application of voriconazole

Also Published As

Publication number Publication date
SE0403004D0 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
US5708175A (en) Process for producing 4-trifluoromethylnicotinic acid
JP3055819B2 (en) 2-thienylglycidic acid derivative and method for producing the same
JP2005501841A5 (en)
JPH0794420B2 (en) Process for producing substituted phenoxyacetaldehyde oximes
KR101100064B1 (en) Method for preparing nitrooxy derivatives of naproxen
EP2298756B1 (en) Method for producing 3-methyl-2-thiophenecarboxylic acid
WO2006062477A1 (en) Chemical process
US4501919A (en) Process for the production of serine derivatives
US3952010A (en) Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles
HU194861B (en) Process for production of derivatives of 2-/2-tienil/and 2-/3-tienil/-ethil-amin in form of acid-additioned salts
US6380436B1 (en) Process for the synthesis of alkoxyalkyl (trifluormethylphenyl) methanones
JP3810858B2 (en) Process for producing 4-trifluoromethylnicotinic acid
CN115260103B (en) Preparation method of 4,5-dihalogen-1- (difluoromethyl) -1H-imidazole
JP4582286B2 (en) Sulfooxyalkynylthiophene compound and process for producing the same
JP2583791B2 (en) Production method of halogenated ethylbenzene
EP3950659B1 (en) Method for preparing 2-arylmalonic acid derivative, intermediate, and application thereof
US4220794A (en) Synthetic intermediates for the preparation of diaromatic O-(amino-alkyl)oximes
US5498725A (en) Process for preparing 5-aminodihydropyrrole intermediate thereof and process for preparing said intermediate
JPH0657698B2 (en) Pyrazol oxime derivative and method for producing the same
US4798893A (en) Process for producing 1-(5-substituted-2-ethynylphenyl)-2-propanones
KR930003756B1 (en) Method for preparing substituted β-phenylacrylic acid
KR100390026B1 (en) Preparation method of N-methyl-3-[(4-trifluoromethyl) phenoxy] -3-phenylpropylamine
JPS6045542A (en) Method for producing 3-halogeno-4-alkoxyneophyl halide
JP2003517029A (en) Method for producing trifluoromethylacetophenone
JPH04187667A (en) Production of 2-substituted hydroxyiminopropanedinitrile

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815796

Country of ref document: EP

Kind code of ref document: A1